Efficacy of teicoplanin and imipenem on respiratory infections in high risk patients.
The efficacy of teicoplanin and imipenem was assayed on microorganisms, mainly hospital opportunistic organisms, resistant to common therapy, isolated from bronchoaspirates of high risk hospitalized patients. Imipenem has shown remarkable activity against all isolated microorganisms with sensitivities ranging from 91.93% against Acinetobacter calcoaceticus to 75.86% against Pseudomonas sp. Teicoplanin has shown excellent activity against Staphylococcus aureus (sensitivity 83.66%).
Piu
G
G
Laboratorio Microbiologia e Virologia, Ospedale S Michele, Cagliari, Italy.
Aresu
G
G
Pautasso
M
M
Garau
G
G
Melis
S
S
Ceccio
S
S
Morini
M
M
Palomba
A
A
D000151:Acinetobacter Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy*; D017334:Teicoplanin / Q000008:administration & dosage / Q000494:pharmacology*; D013845:Thienamycins / Q000008:administration & dosage / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D017334:Teicoplanin; D015378:Imipenem